{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T22:41:50Z","timestamp":1648593710764},"reference-count":35,"publisher":"ClinTransMed, AB","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Bioinform"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13336-015-0020-x","type":"journal-article","created":{"date-parts":[[2015,4,27]],"date-time":"2015-04-27T10:42:41Z","timestamp":1430131361000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative efficacy and acceptability of five anti-tubercular drugs in treatment of multidrug resistant tuberculosis: a network meta-analysis"],"prefix":"10.26781","volume":"5","author":[{"given":"Huaidong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanxiang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zipeng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11322","published-online":{"date-parts":[[2015,4,28]]},"reference":[{"issue":"10","key":"20_CR1","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/ng.2744","volume":"45","author":"I Comas","year":"2013","unstructured":"Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato-Maeda M, et al. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet. 2013;45(10):1176\u201382.","journal-title":"Nat Genet"},{"issue":"7","key":"20_CR2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1586\/eri.10.60","volume":"8","author":"E Leibert","year":"2010","unstructured":"Leibert E, Rom WN. New drugs and regimens for treatment of TB. Expert Rev Anti Infect Ther. 2010;8(7):801\u201313.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"RR-09","key":"20_CR3","first-page":"1","volume":"62","author":"Prevention CfDCa","year":"2013","unstructured":"Prevention CfDCa. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep. 2013;62(RR-09):1\u201312.","journal-title":"MMWR Recomm Rep"},{"key":"20_CR4","volume-title":"Multidrug-resistant TB (MDR-TB): 2013 Update","author":"Organization WH","year":"2013","unstructured":"Organization WH. Multidrug-resistant TB (MDR-TB): 2013 Update. 2013. http:\/\/www.who.int\/tb\/challenges\/mdr\/mdr_tb_factsheet.pdf?ua=1 ."},{"key":"20_CR5","unstructured":"Organization GWH. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. WHO Guidelines Approved by the Guidelines Review Committee 2013."},{"issue":"2","key":"20_CR6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jiph.2013.09.001","volume":"7","author":"S Ahmad","year":"2014","unstructured":"Ahmad S, Mokaddas E. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. J Infect Public Health. 2014;7(2):75\u201391.","journal-title":"J Infect Public Health"},{"issue":"3","key":"20_CR7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MCP.0b013e32835f1bf3","volume":"19","author":"E Pontali","year":"2013","unstructured":"Pontali E, Matteelli A, Migliori GB. Drug-resistant tuberculosis. Curr Opin Pulm Med. 2013;19(3):266\u201372.","journal-title":"Curr Opin Pulm Med"},{"key":"20_CR8","unstructured":"The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva: World Health Organization; 2013."},{"issue":"9","key":"20_CR9","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40265-014-0241-5","volume":"74","author":"NJ Ryan","year":"2014","unstructured":"Ryan NJ, Lo JH. Delamanid: first global approval. Drugs. 2014;74(9):1041\u20135.","journal-title":"Drugs"},{"issue":"4","key":"20_CR10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1517\/14656566.2012.657176","volume":"13","author":"M Lauzardo","year":"2012","unstructured":"Lauzardo M, Peloquin CA. Antituberculosis therapy for 2012 and beyond. Expert Opin Pharmacother. 2012;13(4):511\u201326.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"20_CR11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/cid\/cis849","volume":"56","author":"RS Wallis","year":"2012","unstructured":"Wallis RS. Sustainable tuberculosis drug development. Clin Infect Dis. 2012;56(1):106\u201313.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"20_CR12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/0255-0857.99481","volume":"30","author":"NK Dutta","year":"2012","unstructured":"Dutta NK, Karakousis PC. Tuberculosis chemotherapy : present situation, possible solutions, and progress towards a TB-free world. Indian J Med Microbiol. 2012;30(3):261\u20133.","journal-title":"Indian J Med Microbiol"},{"issue":"9799","key":"20_CR13","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","volume":"378","author":"A Cipriani","year":"2011","unstructured":"Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378(9799):1306\u201315.","journal-title":"Lancet"},{"issue":"3","key":"20_CR14","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","volume":"48","author":"CP Cannon","year":"2006","unstructured":"Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3):438\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"20_CR15","doi-asserted-by":"crossref","first-page":"e76651","DOI":"10.1371\/journal.pone.0076651","volume":"8","author":"J Liu","year":"2013","unstructured":"Liu J, Dong J, Wang L, Su Y, Yan P, Sun S. Comparative efficacy and acceptability of antidepressants in Parkinson\u2019s disease: a network meta-analysis. PLoS One. 2013;8(10):e76651.","journal-title":"PLoS One"},{"issue":"9665","key":"20_CR16","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","volume":"373","author":"A Cipriani","year":"2009","unstructured":"Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746\u201358.","journal-title":"Lancet"},{"issue":"2","key":"20_CR17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nbt0213-89","volume":"31","author":"R Osborne","year":"2013","unstructured":"Osborne R. First novel anti-tuberculosis drug in 40\u00a0years. Nat Biotechnol. 2013;31(2):89\u201391.","journal-title":"Nat Biotechnol"},{"issue":"16","key":"20_CR18","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","volume":"21","author":"T Lumley","year":"2002","unstructured":"Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21(16):2313\u201324.","journal-title":"Stat Med"},{"issue":"9896","key":"20_CR19","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362.","journal-title":"Lancet"},{"issue":"2","key":"20_CR20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3904\/kjim.2011.26.2.153","volume":"26","author":"J Lee","year":"2011","unstructured":"Lee J, Lee CH, Kim DK, Yoon HI, Kim JY, Lee SM, et al. Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes. Korean J Intern Med. 2011;26(2):153\u20139.","journal-title":"Korean J Intern Med"},{"issue":"1","key":"20_CR21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijantimicag.2013.02.019","volume":"42","author":"RH Jiang","year":"2013","unstructured":"Jiang RH, Xu HB, Li L. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study. Int J Antimicrob Agents. 2013;42(1):36\u201341.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"20_CR22","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/AAC.06126-11","volume":"56","author":"AH Diacon","year":"2012","unstructured":"Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56(6):3271\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"23","key":"20_CR23","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","volume":"360","author":"AH Diacon","year":"2009","unstructured":"Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397\u2013405.","journal-title":"N Engl J Med"},{"key":"20_CR24","unstructured":"BVBA JID. TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB). Clinical Trialsgov. 2013. ( https:\/\/www.clinicaltrials.gov\/ct2\/results?term=+Anti-bacterial+Activity%2C+Safety%2C+and+Tolerability+of+TMC207+in+Participants+With+Multi-drug+Resistant+Mycobacterium+Tuberculosis+%28MDR-TB%29&Search=Search )"},{"issue":"23","key":"20_CR25","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","volume":"366","author":"MT Gler","year":"2012","unstructured":"Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151\u201360.","journal-title":"N Engl J Med"},{"key":"20_CR26","unstructured":"Otsuka Pharmaceutical Development & Commercialization I. A Placebo-controlled, Phase 2 Trial to Evaluate OPC 67683 in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB). Clinical Trialsgov. 2011. ( https:\/\/www.clinicaltrials.gov\/ct2\/results?term=A+Placebo-controlled%2C+Phase+2+Trial+to+Evaluate+OPC+67683+in+Patients+With+Pulmonary+Sputum+Culture-positive%2C+Multidrug-resistant+Tuberculosis+&Search=Search )"},{"issue":"6","key":"20_CR27","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1183\/09031936.00125812","volume":"41","author":"V Skripconoka","year":"2012","unstructured":"Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2012;41(6):1393\u2013400.","journal-title":"Eur Respir J"},{"issue":"3","key":"20_CR28","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s12013-013-9589-5","volume":"67","author":"Q Zhang","year":"2013","unstructured":"Zhang Q, Liu Y, Tang S, Sha W, Xiao H. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China. Cell Biochem Biophys. 2013;67(3):957\u201363.","journal-title":"Cell Biochem Biophys"},{"issue":"8","key":"20_CR29","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1128\/AAC.00753-13","volume":"57","author":"MW Carroll","year":"2013","unstructured":"Carroll MW, Jeon D, Mountz JM, Lee JD, Jeong YJ, Zia N, et al. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57(8):3903\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"20_CR30","unstructured":"Center NIoHC. Metronidazole for pulmonary tuberculosis (South Korea). Clinical Trialsgov 2013. ( https:\/\/www.clinicaltrials.gov\/ct2\/results?term=Metronidazole+for+pulmonary+tuberculosis+%28South+Korea%29&Search=Search )"},{"key":"20_CR31","unstructured":"University JH. Moxifloxacin as part of a multi-drug regimen for tuberculosis. Clinical Trialsgov. 2013.( https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00082173?term=Moxifloxacin+as+part+of+a+multi-drug+regimen+for+tuberculosis&rank=1 )"},{"issue":"2","key":"20_CR32","first-page":"309","volume":"18","author":"Y Chen","year":"2013","unstructured":"Chen Y. Effects of moxifloxacin combined with regimenin the treatment of patients with drug-resistant pulmonary tuberculosis. J Clin Pulm Med. 2013;18(2):309\u201310.","journal-title":"J Clin Pulm Med"},{"issue":"7","key":"20_CR33","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1164\/rccm.201303-0604OC","volume":"188","author":"WJ Koh","year":"2013","unstructured":"Koh WJ, Lee SH, Kang YA, Lee CH, Choi JC, Lee JH, et al. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2013;188(7):858\u201364.","journal-title":"Am J Respir Crit Care Med"},{"key":"20_CR34","unstructured":"Hospital SNU. Comparison of the effect between levofloxacin and moxifloxacin among MDR-TB patients. Clinical Trialsgov. 2012. ( https:\/\/www.clinicaltrials.gov\/ct2\/results?term=Comparison+of+the+effect+between+levofloxacin+and+moxifloxacin+among+MDR-TB+patients&Search=Search )"},{"issue":"5A","key":"20_CR35","first-page":"1451","volume":"14","author":"L Liang","year":"2011","unstructured":"Liang L. Effects of anti-tuberculosis containing with moxifloxacin or levofloxacin on multidrug resistant pulmonary tuberculosis. Chin Gen Pract. 2011;14(5A):1451\u20138.","journal-title":"Chin Gen Pract"}],"container-title":["Journal of Clinical Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13336-015-0020-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T15:54:55Z","timestamp":1506527695000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jclinbioinformatics.com\/content\/5\/1\/5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,28]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["20"],"URL":"https:\/\/doi.org\/10.1186\/s13336-015-0020-x","relation":{},"ISSN":["2043-9113"],"issn-type":[{"value":"2043-9113","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,28]]},"article-number":"5"}}